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Activation of PPAR Specifies a Dendritic Cell
Subtype Capable of Enhanced Induction
of iNKT Cell Expansion
in these tissues (Summers et al., 2001). A major step
of T cell activation is the presentation of processed
peptides by MHC class II and/or class I membrane pro-
teins. DCs also have the capacity to present lipid anti-
gens to specialized T cells by CD1 proteins. CD1 surface
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the autoreactive natural killer T (NKT) cell population,
which is characterized by the invariant V24 to J15
rearrangement preferentially in pair with V11 (iNKT cell)Summary
(Brossay et al., 1998). iNKT cells can be activated by
-galactosyl-ceramid (-GalCer) in the context of CD1dLittle is known of the transcriptional events controlling
(Kawano et al., 1997). Interestingly, the lack of iNKT cellthe differentiation and function of dendritic cells (DC).
activation has been implicated in the development ofWe found that the ligand-activated transcription factor
autoimmune conditions (Hammond and Kronenberg,Peroxisome Proliferator Activated Receptor (PPAR)
2003), and iNKT cells were shown to be defective inis immediately upregulated after the induction of mono-
nonobese diabetic (NOD) mice, a model of autoimmunecyte-derived DC differentiation. Activation of PPAR
(type 1) diabetes (Carnaud et al., 2001; Kukreja et al.,changed the expression pattern of cell surface recep-
2002). This suggests that iNKT cells are intimately linkedtors and enhanced the internalizing activity of DC. Un-
to sustaining immunological tolerance.expectedly, we found that CD1 glycoproteins, a class
Monocytes can be differentiated ex vivo to DCs cultur-of molecules responsible for the presentation of self
ing them with GM-CSF and IL-4 (Sallusto and Lanzavec-and foreign modified lipids, were coordinately regu-
chia, 1994). Monocytes are capable to differentiate intolated by PPAR activation. CD1a levels were reduced,
DCs in vivo after transendothelial transport (Randolphwhile CD1d expression was induced. Enhanced ex-
et al., 1998). Monocyte-to-DC transition is greatly en-pression of CD1d was coupled to the selective induc-
hanced by a phagocytic stimulus (Randolph et al., 1999),tion of invariant natural-killer T cell (iNKT cell) prolifer-
suggesting that this process has an antigen-dependentation in the presence of -GalCer. These results
component. In search for a mechanism to connect anti-suggest that PPAR orchestrates a transcriptional re-
gen uptake and the induction of monocyte-derived DCsponse leading to the development of a DC subtype
differentiation, we evaluated the role of lipid-activatedwith increased internalizing capacity, efficient lipid
nuclear hormone receptors, the Peroxisome Proliferatorpresentation, and the augmented potential to activate
Activated Receptors (PPARs). The reasons that led us
iNKT cells.
to look into the potential role of PPARs in monocyte-
derived DC differentiation were the fact that PPAR is
Introduction expressed in both macrophages (Tontonoz et al., 1998)
and dendritic cells (Faveeuw et al., 2000; Gosset et al.,
Dendritic cells (DCs) are professional antigen-present- 2001; Nencioni et al., 2002), and a key surface receptor
ing cells, possessing a unique capacity to prime naive associated with the uptake of apoptotic cells, the scav-
T cells (Banchereau and Steinman, 1998). Myeloid DCs enger receptor CD36 (Albert et al., 1998), is known to
exist in two functionally distinct states, immature and be regulated by PPAR (Tontonoz et al., 1998). PPAR
mature. The capacity to internalize antigen is a property is a member of the nuclear hormone receptor superfam-
of immature DC (IDC). IDCs sample and internalize exter- ily. It is a lipid-activated transcription factor regulating
nal antigens and target them to MHC class II positive genes of lipid uptake, accumulation, and storage (Will-
lysosomes (Sallusto et al., 1995). After detecting micro- son et al., 2001). It is also part of a network of transcrip-
bial products or pro-inflammatory cytokines, IDCs trans- tional regulators coordinately regulating lipid uptake and
form into mature DCs, with an exceptional capacity for cholesterol efflux in macrophages by transcriptionally
T cell activation. This takes place in vivo in lymphoid regulating CD36 and the oxysterol receptor LXR
tissues such as the lymph nodes and tonsils. Indeed, (Chawla et al., 2001b; Repa et al., 2000).
multiple subsets of dendritic cells have been identified We examined the role of PPAR in dendritic cell differ-
entiation and function using human monocyte-derived
DC as a model system. We found that PPAR is immedi-*Correspondence: lnagy@indi.biochem.dote.hu
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ately upregulated after the induction of the differentia- ligand/activator of PPAR may be present or are gener-
ated during this differentiation process. To address thistion of DCs. We detected an increased expression of
issue, we used a specific antagonist of PPAR (GW9662)CD1d in DC by ligand activation of PPAR, which if
for inhibiting target gene expression. GW9662 was ablecoupled to the presentation of -GalCer led to the selec-
to prevent the upregulation of FABP4 (Figure 1E) in bothtive induction of iNKT cell proliferation. Our data
untreated and ligand-treated cells. Next, we looked atpresented here suggest that the lipid-activated tran-
the effect of a synthetic thiazolidinedione, Rosiglitazonescription factor, PPAR, is involved in orchestrating a
(RSG), on PPAR-regulated gene expression. The com-transcriptional response in differentiating monocyte-
pound was added to the culture upon the initiation ofderived DCs, leading to the development of a dendritic
DC differentiation. The transcript level of FABP4 wascell subtype with increased internalizing capacity, effi-
consistently and significantly upregulated as a result ofcient lipid presentation, and the ability to induce iNKT
ligand treatment (Figure 1E). Other target genes suchcell proliferation.
as LXR or PGAR (Chawla et al., 2001b; Yoon et al.,
2000) were also upregulated after treatment with theResults
PPAR-specific agonist (data not shown). It was also
noted that FABP4 levels got induced to a higher levelPPAR Is an Immediate Early Gene
in human AB serum than in FBS (fetal bovine serum)during Monocyte-Derived DC Differentiation
(Figure 1E), suggesting that human AB serum containsIn order to provide a baseline for our studies, we exam-
and/or induces endogenous ligands/activators. Thisined the expression pattern of the different PPAR iso-
more pronounced increase could also be blocked effec-forms in monocytes and monocyte-derived DCs. Mono-
tively by the PPAR antagonist (Figure 1E). We alsocytes were cultured in the presence of GM-CSF and IL-4
monitored the degree of PPAR responsiveness duringfor 5 days to generate IDCs. First, we assessed the
the course of DC differentiation. Differentiation was initi-mRNA levels of PPARs in monocytes and IDCs using
ated, specific ligand was added at 0, 1, 2, 3, or 4 days,real-time quantitative RT-PCR. By using this technique,
and FABP4 expression levels were determined (Figuretranscript levels of the various receptors could be di-
1F). The highest level of response could be achieved ifrectly compared. PPAR was barely detectable in freshly
the cells were exposed to the ligand in the first 24 hr ofisolated monocytes, but it was significantly upregulated
differentiation. This coincides with the highest level ofduring DC differentiation (Figure 1A). The transcript level
PPAR expression (Figure 1B). These results estab-of PPAR was also increased during this differentiation
lished that PPAR is promptly expressed at high levelsprocess (Figure 1A). The mRNA level of PPAR was
in differentiating DCs, it is transcriptionally active, andrelatively low in monocytes and only slightly increased
most likely it is activated by endogenous ligand(s). Thein IDCs (Figure 1A). Based on these results, we con-
highest level of receptor expression and ligand respon-cluded that in monocyte-derived DCs, the dominant iso-
siveness occurs in the first 24 hr of differentiation.types of PPARs are PPAR and PPAR. It should be
To assess the consequences of PPAR activation fornoted that PPAR was induced to a larger extent than
DC differentiation and function, we carried out an exten-PPAR. Interestingly, we found a very rapid increase of
sive analysis of differentiation markers, gene expressionPPAR mRNA already after 1 hr in culture, reaching its
profiles, and functional studies (antigen uptake, T cellhighest level between 2 and 4 hr and then decreasing
activation, cytokine production).slightly by 24 hr (Figure 1B). We also assessed the pro-
tein expression of PPAR by immunoblot. As shown in
PPAR Agonists Modulate the Expression
Figure 1D, PPAR protein was present after 4 hr, and
of DC-Specific Membrane Proteins
after 12 hr in culture we detected a substantial increase
We measured the cell surface expression of monocyte-
of PPAR protein, in line with the increased mRNA ex- and DC-specific membrane proteins by flow cytometry.
pression levels. In agreement with a previous publication (Nencioni et
al., 2002), addition of the PPAR activator induced
PPAR Is Functional and Active in DCs and Can Be changes of the pattern of cell surface molecules: CD86
Further Activated by Exogenous Ligands and HLA-DR expression were increased, while CD80
To verify if PPAR is active or can be activated during and CD1a were decreased on IDCs generated in the
DC development, cells were treated with specific ago- presence of PPAR-specific ligand (data not shown). It
nists of PPAR, and mRNA expression of known target is important to note that ligand treatment was most
genes were measured by RT-PCR. Our microarray data efficient if added at the beginning of the differentiation
indicated that the adipocyte-specific fatty acid binding process (Figure 1F). As a consequence of ligand treat-
protein (FABP4 or aP2), a target gene of PPAR (Tonto- ment, IDCs remained CD14 negative and the expression
noz et al., 1995), was a sensitive marker of PPAR activ- of DC-SIGN (CD209) was unchanged or in some cases
ity (data not shown). Therefore, we used it as an indicator marginally decreased (data not shown). These data indi-
of activation of PPAR, both as an endpoint for as- cate that RSG treatment does not inhibit but modifies
sessing the presence of endogenous ligands and also DC differentiation, and as a consequence the expression
as the measure of exogenous ligand activation. First, of some DC markers is changed. Next, we studied the
we looked at the expression of PPARand FABP4 during effect of PPAR activation on key functions of DC.
the course of DC differentiation. As shown in Figure 1B,
PPAR is acutely upregulated within 1 hr and this is RSG-Treated Immature DCs Display Enhanced
followed by the induction of FABP4 after 4 hr, suggesting Endocytotic Activity
that the receptor is activated by endogenous ligands Endocytosis is a hallmark of immature DCs. Therefore,
we were interested to test if activation of PPAR had any(Figure 1C). These data indicate that some endogenous
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Figure 1. PPAR Expression Is Rapidly In-
creased during DC Differentiation and the
Receptor Can Be Activated by PPAR-Spe-
cific Agonist
(A) Monocytes were cultured for 24 hr or 5
days in the presence of 500 U/ml IL-4 and
800 U/ml GM-CSF for the generation of IDCs.
The mRNA levels for PPARs were determined
by real-time quantitative RT-PCR as de-
scribed in Experimental Procedures. Data are
expressed as a ratio of the PPAR transcripts
relative to 36B4 expression. Data show the
average expression and standard deviation
of five independent experiments.
(B and C) Kinetics of PPAR and FABP4 ex-
pression. Cells were harvested at the indi-
cated points of time and the mRNA expres-
sion was determined by RT-PCR. All PCR
data are expressed as a ratio of the PPAR or
FABP4 transcripts relative to 36B4 expres-
sion. Error bars indicate the standard devia-
tion of the relative expression.
(D) Western blot analysis of PPAR protein
expression in differentiating DC. 20 g of ex-
tract from the indicated cell types were sepa-
rated by SDS-PAGE, transferred to PDVF
membrane, and subjected to Western blot
analysis using rabbit anti-PPAR (H-100;
Santa Cruz) and anti-GAPDH (Sigma) anti-
bodies. The identity of the 55 kDa band was
confirmed by comigration with a band seen
in the cell extract of PPAR-transduced 293
cells.
(E) Determination of the transcript levels of
FABP4 of vehicle or 2.5 M Rosiglitazone
(RSG)-treated DC in the presence or absence
of 5 M GW9662. Cells were cultured using
10% FBS (fetal bovine serum) or FBS was
replaced with human AB serum.
(F) Kinetics of FABP4 expression. IDCs were
harvested and analyzed on day 5. The ligand
treatment (2.5M RSG) was performed at the
indicated time points.
influence on this activity. The capacity of RSG-treated had similar capacity as highly positive cells to uptake
latex beads (data not shown), suggesting that CD36immature DCs to take up antigens was measured by
two methods: (1) internalization of FITC-dextran, which expression may not account for increased uptake of
latex beads.is mainly taken up by mannose receptor-mediated endo-
cytosis, and (2) engulfment of latex beads for detection In line with previous results (Sallusto et al., 1995),
mannose receptor (CD206), which is involved in FITC-of phagocytosis. RSG did not influence FITC-dextran-
dependent endocytosis of DC but enhanced the uptake dextran uptake, was induced in IDCs (Figure 2A) and
remained unaltered by PPAR activator treatment,of latex beads (Figure 2A). Monocytes also possess high
capacity of latex bead uptake, and RSG-treated cells which further underscores the notion that PPAR activa-
tion does not inhibit DC differentiation. A recent paperretained this activity. In immature DCs, a number of cell
surface receptors are involved in antigen uptake. One suggested that PPAR ligand may promote mannose
receptor gene expression in murine macrophagesof them is CD36, which may act as a receptor for apo-
ptotic cell uptake and has been postulated to mediate (Coste et al., 2003), but in human monocyte-derived DC
we could not detect upregulation of this protein uponcross priming of cytotoxic T cells by human DCs (Albert
et al., 1998). It is also a known target of PPAR (Tontonoz RSG treatment.
et al., 1998). We examined the cell surface expression
of CD36 during DC development and detected higher RSG-Treated MDCs Have an Unaltered T
Lymphocyte Stimulatory Capacityexpression of CD36 on PPAR activator-treated IDCs
than on control cells (Figure 2A). The detailed analysis An important aspect of dendritic cell function is the
ability of DCs to activate T cells. We first determinedof CD1a and CD36 expression in correlation with latex
bead uptake revealed that CD1a-negative cells had a the effect of RSG on the expression of surface markers
on mature DC. As shown in Figure 3A, MDCs becomehigher capacity of engulfing latex beads than CD1a-
positive cells (Figure 2B). We observed that in some CD83 positive and upregulate the expression of HLA-
DR and the costimulatory molecules CD80 and CD86.individuals RSG-treated DCs could be divided into high
and low expressors of CD36. However, CD36low cells Upon maturation of DCs in the presence of a PPAR-
Immunity
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Figure 2. Activation of PPAR Enhances the Phagocytic Activity of IDCs
(A) Monocytes (Mono) were cultured for 5 days as described in Experimental Procedures in the presence (IDC RSG) or the absence (IDC) of
2.5 M RSG. The phagocytic capacity of DC was evaluated by measuring the uptake of FITC-dextran or latex bead as described in the
Experimental Procedures. Cell surface expression of CD36 and CD206 was determined by flow cytometry. Cell surface receptor-specific mAb
indicated (solid line) versus isotype-matched control (dotted line).
(B) Latex bead uptake (4 hr incubation) of the CD1a and CD1a DC was measured by flow cytometry.
specific activator, CD80 was slightly downregulated, but sults indicate that PPAR ligand treatment does not
impede the T cell stimulatory capacity of the DCs andthe expression of the other cell surface molecules tested
on MDC did not change (Figure 3A). Next, we assessed does not interfere with the maturation of DCs.
the stimulatory capacity of MDCs to elicit proliferative
responses of alloreactive T lymphocytes. We found that Activation of PPAR Coordinately Modulates
the Expression of CD1s during DC Differentiationthe stimulatory capacity of RSG-treated mature DC for
T cells was comparable to that of control MDC (Figure After assessing the effect of PPAR activation on known
genes implicated in DC differentiation and function, we3B). To further explore the potential effects of PPAR
activation of DC on lymphocyte activation, we measured embarked on a more comprehensive analysis of gene
expression using global gene expression profiling. AnIFN production in mixed leukocyte reaction (MLR) by
ELISA (Figure 3C) and also performed two-color flow important family of genes showing differential regulation
was the CD1 family. Intriguingly, the CD1 proteins havecytometric analysis of T cells to assess the expression
of CD25, a lymphocyte activation marker (Figure 3D). been implicated in lipid antigen presentation (Porcelli,
1995).We observed that PPAR ligand (2.5M RSG) treatment
of the differentiating DCs did not impair IFN production CD1a is highly upregulated during monocyte-derived
DC differentiation using FBS containing cell-culture me-and activation of allogeneic T lymphocytes. These re-
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Figure 3. PPAR Treatment Does Not Interfere with DCs Maturation
Monocytes (Mono) were cultured for 6 days as described in Experimental Procedures for the generation of MDC.
(A) Phenotypic characterization of MDC. MDCs were stained with mAbs indicated in the figure. Cell surface molecule-specific mAb indicated
(solid line) versus isotype-matched control (dotted line).
(B) MDCs or RSG-treated MDCs were cocultured with allogeneic PBMC (2  105/well) at ratios ranging between 1:10 and 1:640 (DC:T cells)
for 5 days. [3H]thymidine (1 Ci/well) was added for the last 16 hr of the cultures, the cells were harvested, and proliferation was measured
by detecting [3H]thymidine incorporation by a scintillation counter.
(C) MDCs or RSG- (2.5 M) treated MDCs were cocultured with allogeneic PBMC (2  105/well) at 1:10 DC-T cell ratio. Supernatants were
collected at day 5 and were assayed by INF ELISA. Results are represented as mean and SD of four independent experiments.
(D) MDC or RSG- (2.5 M) treated MDC were cocultured with allogeneic PBMC (2  105/well) at 1:10 DC-T cell ratio. PBMCs were harvested
at day 5 and analyzed by FACS. Cells were stained by two-color flow cytometry using the indicated T cell-specific Abs. In the T cell controls,
the proportion of CD25 cells was 3.03% of the total lymphocyte population.
dium. We and others observed that addition of RSG at of conserved transmembrane proteins structurally re-
lated to MHC class I proteins (Calabi et al., 1989). Wethe initiation of DC differentiation resulted in marked
inhibition of CD1a expression (Nencioni et al., 2002; data found that freshly isolated monocytes were devoid of
expression not only of CD1a but also the rest of thenot shown). Since the most pronounced effect of PPAR
activators on DC was the selective downregulation of group I CD1s (CD1b, CD1c, and CD1e). The transcript
levels of these genes were strongly increased on imma-CD1a and this change correlated with a significantly
increased endocytic capacity, we analyzed the ligand’s ture DC, and as a result of ligand treatment the mRNA
levels of these genes were much lower (Figure 4A). Un-effect on the expression of the entire CD1 gene family.
We determined the transcript level of CD1 family mem- expectedly, CD1d (group II CD1) showed a completely
different expression pattern. Monocytes were CD1dbers during DC differentiation using Affymetrix microar-
ray analysis (HU95A). The CD1 locus encodes a family positive but DC expressed very low levels of CD1d
Immunity
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Figure 4. PPAR-Activated DCs Express
More CD1d and Less CD1a than Nontreated
Cells
Monocytes (Mono) were cultured for 5 days
as described in Experimental Procedures in
the presence (IDC RSG) or the absence (IDC)
of 2.5 M RSG.
(A and B) The relative expression of group I
CD1s and CD1d, respectively, were assessed
by using affymetrix microarray data as de-
scribed in Experimental Procedures.
(C and D) The mRNA level of CD1a and CD1d
were determined by RT-PCR. RT-PCR analy-
ses of six independent experiments are shown.
mRNA (Figure 4B). RSG-treated cells showed a retained it was downregulated during the beginning of DC differ-
entiation regardless of the PPAR agonist treatment.CD1d expression. The typical expression pattern of
CD1a and CD1d was confirmed by RT-PCR (Figures After 12 hr, we measured very low expression of CD1d,
but after 5 days we detected a net induction of CD1d4C and 4D) in six independent samples. To assess the
receptor specificity of this regulation, we used a panel in PPAR-activated cells (Figure 5F). These data suggest
that PPAR activators not simply attenuate the de-of synthetic receptor-specific agonists to see if activa-
tion of PPAR (Wy16643), PPAR (GW501516), and creased expression of CD1d but instead (probably indi-
rectly) induce CD1d expression in DCs.LXRs (T0901317), which are also expressed in differenti-
ating DCs, produce a similar effect on CD1d expression.
We also used other structurally distinct synthetic and RSG-Treated DC Express More CD1d and Have an
Improved Capacity to Induce iNKT Cell Expansionnatural PPAR agonists/activators (GW7845, oxidized
LDL) alone or in combination with the PPAR antagonist The induced CD1d and the reduced CD1a protein ex-
pression was detected on the cell surface of PPAR(GW9662) to prove the receptor selectivity of the effect.
We compared the expression of a bona fide target gene agonist (RSG)-treated IDCs and MDCs as shown in Fig-
ures 6A and 6B in agreement with the mRNA expression.FABP4 to that of CD1d. As shown on Figure 5A, induc-
tion of FABP4 is specifically upregulated by PPAR ago- The finding that RSG-treated monocyte-derived DCs ex-
press more CD1d mRNA and protein then untreatednists and much less potently by a PPAR activator. The
regulation of CD1d showed a similar but distinct pattern. cells focused our attention on the physiological conse-
quence of increased CD1d expression on DC. CD1d-Besides PPAR activators (RSG, GW7845), PPAR
(GW501516) and PPAR (Wy14,643) activators could mediated glycolipid presentation is indispensable for
the activation and expansion of iNKT cells (Brossay etalso turn on gene expression, though to a lesser extent
(Figure 5B). The PPAR-specific induction of FABP4 and al., 1998). We reasoned that increased CD1d protein
levels should translate into increased activation of iNKTCD1d was inhibited by the specific antagonist (Figures
5C and 5D). It was reported that PPAR activation in- cell. We assessed the relative potency of DCs to induce
iNKT cell proliferation in autologous MLR cultures. DCsduces LXR in macrophages (Chawla et al., 2001b) and
we confirmed this result in DC (data not shown), so it were pulsed with -GalCer in vitro for 24 hr with or
without an inflammatory cocktail to obtain -GalCer-is possible that CD1d got activated indirectly via the
activation of LXR. Our data show that this is unlikely loaded MDCs or IDCs, respectively, and used as stimula-
tory cells for monocyte-depleted autologous PBMC into be the case because the LXR activator (T0901317)
failed to induce CD1d (Figure 5B). We previously de- a 5-day culture. We determined the percent of iNKT cells
using two-color flow cytometry for the detection of thescribed that the naturally occurring pathogenic lipopro-
tein oxLDL contains PPAR agonists (Nagy et al., 1998), cells harboring V24 V11 invariant T cell receptors.
We observed that-GalCer was necessary for the potentand we observed that oxLDL induced FABP4 and CD1d
expression in DCs (Figures 5C and 5D). It is noteworthy induction of V24 V11 cells expansion. Without this
glycolipid, we obtained less than 1% iNKT cells after 5that oxLDL induced CD1d levels to a much higher level
than predicted by its potential to activate PPAR (com- days of coculture (data not shown). However, we de-
tected a remarkable expansion of iNKT cells when thepare Figures 5C and 5D). This suggests that oxLDL may
utilize both a PPAR-dependent and -independent path- cells were loaded with -GalCer and this was further
enhanced in presence of RSG-treated IDC (Figure 6C).way for turning on CD1d.
We compared the kinetics of the induction of FABP4 We repeated this experiment several times and obtained
inductions ranging from 1.5- to 10.25-fold (n 	 8) de-and CD1d during the course of DC differentiation. We
observed that after 12 hr FABP4 was highly induced pending on the donor. Interestingly, using MDCs as
stimulator, we consistently observed a more moderateupon ligand treatment (Figure 5E). The freshly isolated
monocytes express a significant amount of CD1d and effect of the PPAR ligand treatment on iNKT expansion
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Figure 5. Comparison of CD1d and FABP4
Expression Patterns during DC Differenti-
ation
(A and B) Transcript levels of FABP4 and
CD1d, respectively, were determined in IDC
treated with various ligands: 2.5M RSG, 200
nM GW7845, 1 M GW501516, 20 M
WY14643, and 1 M T0901317.
(C and D) Determination of FABP4 and CD1d
mRNA levels, respectively, in IDC treated with
2.5 M RSG, in the presence or absence of
5 M GW9662. Cells were also treated with
20 g/ml oxidized LDL.
(E and F) Kinetics of FABP4 and CD1d expres-
sion during IDC differentiation. Cells were
harvested at the indicated points of time and
the mRNA expression was determined by
RT-PCR.
ranging from 1.1- to 4-fold (n 	 8). In order to character- eloid DC did not express PPAR, but after 2 days in
culture PPAR was upregulated. The expression levelize the population of iNKT cells induced by RSG-treated
was 20%–30% of monocyte-derived DCs (Figure 7A).DCs, we also determined the ratio of V24 CD161
Next, we examined the effects of PPAR ligand on thecells. We detected a very similar ratio of double positive
expression of FABP4 in blood DCs. FABP4 was slightlycells if we compared GalCer-loaded control and RSG-
upregulated in PPAR ligand-treated cells (Figure 7B).treated DCs (Figure 6C). Furthermore, the specificity
We also assessed CD1d expression and observed thatand the contribution of the various iNKT subsets to the
cultured DC express less CD1d than freshly isolatedinduced cell population was assessed by -GalCer-
cells but the ligand-treated cells showed an increasedloaded CD1d tetramer staining in combination with anti-
expression of CD1d (Figure 7C). The expression patternCD4 or anti-CD8 antibodies. Human iNKT cells can be
of CD1d was very similar to that of monocyte-deriveddivided into three subsets: DN, CD4, or CD8 subpopu-
DCs although the induction was lower, probably due tolations (Gumperz et al., 2002; Takahashi et al., 2002).
the lower level of PPAR expression.We have determined the distribution of these three sub-
Our results indicate that freshly isolated monocytessets in the induced iNKT cell pool and found that the
and blood-derived DCs lack PPAR, but in vitro differen-ratio of the three subsets was unchanged even though
tiated and cultured cells express this gene at high levels.the number of CD1d tetramer positive cells increased if
It is reasonable to assume that in vivo transmigrationRSG-treated IDCs were used as stimulators.
and/or the local environment contributes to PPAR in-
duction. Factors involved in this induction remain to be
PPAR Can Be Detected in Cultured Myeloid Blood identified. In order to test this scenario, we attempted
DC and in Interdigitating Dendritic Cells of Tonsils to detect PPAR protein in human lymphoid tissue (ton-
In this study, we examined in detail the expression pro- sil) by immunohistochemistry. As shown in Figure 7D,
file of PPAR in monocyte-derived dendritic cells. To nuclear expression of PPAR protein could be detected
extend this study into other in vivo relevant cells, we close to the surface epithelium of the tonsil, a typical
investigated the expression of PPAR in blood DCs. site for the antigen-presenting cells to reside. A few
Dendritic cells can be purified directly from human pe- PPAR-positive cells were also found to be surrounded
ripheral blood, which represents at least three different by lymphoid cells of the perifollicular zones of the tonsil
subsets (Dzionek et al., 2000). We isolated CD1c my- (Figure 7D, insert), indicating DC-T cell interactions. We
eloid DCs from monocyte-depleted PBMC with a yield also stained a similar section with anti-S-100 antibody
of 2–6  106 DCs/500 ml blood. These cells were CD14 (Figure 7E), a marker of activated interdigitating DCs
CD11c and expressed CD1d (data not shown). First, (Laman et al., 2003; Shimizu et al., 2002). Both stainings
we determined the transcript level of PPAR in blood decorated the nonepithelial antigen-presenting cells
with similar distribution patterns (compare Figures 7D toDCs using RT-PCR. We found that freshly isolated my-
Immunity
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Figure 6. PPAR-Activated DCs Express More DC1d and Less CD1a than Their Untreated Counterparts and Promote the Expansion of
iNKT Cells
(A and B) Monocytes (Mono) were cultured for 5 days for obtaining IDC or for 6 days for MDC as described in Experimental Procedures. Cells
were treated with 2.5 M RSG. Monocytes and DCs were harvested and stained with CD1a- or CD1d-specific mAbs (A and B, respectively).
Cell surface-specific mAb indicated (solid line) versus isotype control (dotted line).
(C) -GalCer-pulsed and RSG-treated (2.5 uM) or untreated IDC or MDC were cocultured with autologous PBMC for 5 days and harvested,
and the cells were stained by two-color flow cytometry using the indicated iNKT, T cell-specific Abs, and CD1d tetramer.
7E). Some cells, which co-expressed the nuclear PPAR immunostaining (data not shown). These results support
that at least a subset of S-100 interdigitating dendritic(Figure 7E, inset, arrow) and the cytoplasmic S-100 pro-
tein (arrowhead), could also be found in the lymphoid cells express PPAR in vivo.
compartment. No staining was seen in the nuclei of
lymphocytes. As a positive control for PPAR immuno- Discussion
staining, we detected the PPAR protein in human
brown fat cells obtained from hybernoma (Figure 7F). Although a lot of attention has been focused on the
functional characterization of DC subpopulations, thereNegative control for the staining specificity, sections
incubated with preimmune mouse serum, did not show is very little known on the transcriptional regulation of
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Figure 7. PPAR Is Expressed in Blood DC
and in Interdigitating Dendritic Cells of Hu-
man Tonsils
(A–C) Transcript levels of PPAR, FABP4, and
CD1d, respectively, were determined in
freshly isolated myeloid blood DC (BDCA1)
or BDCA1 cell cultured for 2 days in RPMI
1640 without any cytokine treatment.
(D–F) Expression of PPAR and S-100 in
lymphoid tissue.
(D) Nuclear expression of PPAR protein in
cells (arrow) located in the surface epithelium
of normal human tonsil (40). PPAR-posi-
tive cells were also found surrounded by
lymphoid cells in the perifollicular zones of
the tonsil (inset, 100).
(E) Similar field as shown on (D) exhibits nu-
merous S-100-positive dendritic cells in the
surface epithelium of the tonsil (40). Inset
(100): double-positive cells can be found
in the lymphoid compartments which co-
expressed the nuclear PPAR (arrow) and the
cytoplasmic S-100 protein (arrowhead).
(F) Nuclear expression of PPAR in human
brown fat cells (arrows) obtained from hy-
bernoma.
these differentiation processes. In this work, we at- effects (Chawla et al., 2001a). Using global gene expres-
sion profiling, we also found several positive responses,tempted to assess the contribution of a lipid-activated
transcription factor in monocyte-derived DC differentia- which led us to believe that PPAR may not be simply
an inhibitor of the antigen-presenting functions of DCstion and function. Here, we characterized PPARmRNA
induction and found that it was already at high levels but rather that it modulated their phenotypic features
and functional activities leading to the development ofafter a few hours of DC differentiation. We also deter-
mined the PPAR protein levels and responsiveness of a DC subset.
This appears to be a specification of a subset of DCsdifferentiating DC by measuring target gene expression
and found that both parameters were matching that of rather than inhibition of differentiation per se as sug-
gested by others.the peak of receptor mRNA expression levels. These
findings establish PPAR as an immediate early tran- Being a lipid-activated transcription factor (Willson et
al., 2001), PPAR is ideally suited to coordinate lipidscription factor in monocyte-derived DC differentiation
that brings about increased PPAR responsiveness at a uptake and presentation. Its regulation of CD36 is well
established (Tontonoz et al., 1998); the pivotal role ofvery early stage of DC differentiation. By using receptor-
specific antagonist, we also provided evidence for a CD36 in dendritic cell biology (Urban et al., 2001) and
increasing CD1d mRNA and protein expression all sug-small but detectable level of endogenous ligand activity
stimulating this receptor. An extracellular source could gest a coordinated set of events involving lipid uptake
and presentation. PPAR is a unique transcription factorbe oxidized LDL containing 9- and 13-HODE (Nagy et
al., 1998). Oxidized LDL indeed could modulate DC dif- implicated in both antigen uptake and presentation. It
is intriguing to speculate that there might be a link be-ferentiation from monocytes (Perrin-Cocon et al., 2001),
and our data indicated that oxLDL was able to induce tween the lipid molecules activating PPAR and being
presented by CD1d.the expression of a PPAR target gene in DCs.
It has been shown previously that differentiating DCs Very little is known of the transcriptional regulation of
CD1 genes. Group I CD1 proteins are inducible on hu-express the nuclear hormone receptor PPAR (Gosset
et al., 2001; Nencioni et al., 2002). The results obtained man monocytes by in vitro exposure to GM-CSF or GM-
CSF and IL-4 (Kasinrerk et al., 1993; Porcelli et al., 1992)were mostly inhibitory and suggested that activation of
the receptor inhibited the immunogenicity and cytokine or in vivo after pathogen exposure (Sieling et al., 1999).
Our microarray data indicated that group I CD1s areproduction of DC. We confirmed some of these findings,
but we obtained different results regarding the T cell coordinately upregulated during monocyte-derived DC
differentiation. It was described that RSG-treated DCactivating potential of PPAR-activated DCs. The rea-
son for the differences may be the usage of different express less CD1a (Nencioni et al., 2002). We confirmed
this finding and extended with results showing that theconditions and more importantly different doses of li-
gands. It has been shown that higher doses of PPAR mRNA level of CD1a in ligand-treated cells was also
lower than in control cells. We also found that the activa-activators may induce receptor-independent inhibitory
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tion of PPAR diminished the expression of the whole further investigation into the details of this pathway and
group I CD1s during DC differentiation. The mechanism its utility in the therapy of autoimmune diseases.
of this coordinated decreased expression is unknown.
Experimental ProceduresPPAR ligands negatively regulate the transcription of
inflammatory genes by antagonizing some transcription
Ligandsfactor-mediated pathways (Delerive et al., 2001). A simi-
Rosiglitazone, Wy14643, and T0901317 were from Alexis Biochemi-
lar mechanism might be responsible for the downregula- cals, oxidized LDL from Intracel. GW501516, GW347845X, and
tion of group I CD1s. Interestingly, CD1d is not upregu- GW9662 were provided by T.M. Willson (GlaxoSmithKline, Research
Triangle Park, NC), and -GalCer was obtained from Kirin Brewerylated in GM-CSF- and IL-4-treated human monocytes
Ltd. (Gunma, Japan).in vitro under the same conditions that upregulates
group I CD1s (Exley et al., 2000). Our data show that
DC Generation and MaturationCD1d is downregulated during the course of DC differ-
Monocytes (98% CD14) were obtained from buffy coats by Ficollentiation from monocytes, but PPAR-activated DC in- gradient centrifugation and immunomagnetic cell separation using
duced their CD1d expression after an initial decrease. anti-CD14-conjugated microbeads (VarioMACS; Miltenyi Biotec).
We did not find evidence for a direct effect of PPAR IDCs were prepared as described previously (Sallusto and Lanza-
vecchia, 1994) with minor modification. In brief, monocytes wereon CD1d expression, since a longer exposure time (12
resuspended into 6-well culture dishes at a density of 1.5  106hr) was needed for the increased CD1d expression.
cells/ml and cultured in RPMI 1640 supplemented with 10% FBSNonetheless, we showed that this is a receptor-depen-
(Invitrogen) containing 800 U/ml GM-CSF (Leucomax) and 500 U/mldent process. We believe that CD1d regulation in ligand-
IL-4 (Peprotech). Cells were cultured for 5 or 6 days and the IL-4
treated IDCs is a biphasic process. There is an initial and GM-CSF addition was repeated at day 2. In some experiments,
downregulation not influenced by PPAR activation fol- FBS was replaced with human AB serum (Sigma). To obtain MDCs,
lowed by a PPAR-dependent upregulation. CD1d ex- IDCs were treated with a mix of cytokines: 10 ng/ml TNF-, 10 ng/ml
IL-1, 1000 U/ml IL-6 (Peprotech), 1 g/ml PGE2 (Sigma), and 800pression is indispensable for the generation and expan-
U/ml GM-CSF for 24 hr (Jonuleit et al., 1997).sion of iNKT cells. We detected an increased frequency
Peripheral blood myeloid DCs were magnetically isolated with theof the rare iNKT cells if we cocultured autologous PBMC
CD1c (BDCA-1) Dendritic Cell Isolation Kit (Miltenyi Biotec) from
with RSG-treated and -GalCer-loaded IDC. By charac- monocyte-depleted PBMC. Blood myeloid-DCs (2  105 cells/ml)
terizing the induced iNKT cell population, we found that were cultured for 2 days in RPMI 1640 supplemented with 10% FBS.
it has a similar composition of DN, CD4, and CD8 Ligands or vehicle control (50% DMSO/ethanol) were added to
the cell culture starting from the first day.cells as the control population. The specificity and CD1d
restriction of these cells, proven by CD1d tetramer stain-
Immunohistochemistrying, confirmed the increased lipid presenting capacity
Serial cryosections of tissue samples of human tonsils were usedof RSG-treated IDC.
after 4% paraformaldehyde (pH 7.2) fixation (Tontonoz et al., 1998).
The fact that both in vivo differentiated blood dendritic Endogenous peroxidase was blocked with 0.1 M periodic acid for
cells cultured in vitro and some but not all dendritic cells 10 min. Monoclonal anti-PPAR antibody (E8; Santa-Cruz Biotech-
of lymphoid organs express PPAR suggest that PPAR nology) and polyclonal rabbit antibody specific for the S-100 protein
(Novocastra) were used. Following incubation with primary and bio-is not present in all dendritic cells but rather in a subset
tinylated secondary antibodies, ABC peroxidase was used ac-of dendritic cells in vivo. As far as the signals regulating
cording to the manufacturer’s instructions. Peroxidase activity wasPPAR expression in DCs are concerned, they may be
visualized by the Vector VIP (Vector) substrate. For double staining,associated with transversion of vessel walls, critical
sequential immunolabeling was performed using the Envision sys-
concentration of certain cytokines (i.e., IL-4), or other tem (DAKO) according to the manufacturer’s instruction. Briefly,
factors. We suggest that tissue resident IDC with in- monoclonal antibody to PPAR was visualized with Nickel en-
creased phagocytic and iNKT activating potential may hanced-DAB followed by immunostaining of S-100 protein using
the VIP substrate. Sections were counterstained with 0.2%be involved in the maintenance of peripheral tolerance.
methyl green.There are multiple implications of the pathways dis-
covered. First, this provides a clear insight into how
Quantitation of IFN Production by ELISAextracellular signals can influence cell differentiation
Supernatants of PBMC cultures were stored at80
C until they were
and gene expression. Second, it also provides an entry analyzed for the presence of IFN. Cytokine levels were measured by
point for intervention into this process in vivo by modu- IFN Biosource ELISA kit (Biosource) according to the manufactur-
lating CD1d expression and iNKT cell activation. Third, er’s instructions.
one may speculate on the biological consequences of
Western Blot Analysisincreased CD1d expression and NKT cell activation.
20 g protein whole-cell extract was separated by electrophoresisThere are in vivo examples of CD1d-NKT cell-dependent
in 10% polyacrylamide gel and then transferred to PVDF membraneprocesses such as the NOD mouse. In this model, the
(Bio-Rad Laboratories). Membranes were probed with anti-PPARexpansion and differentiation of autoimmune effector
(H-100) antibody (Santa Cruz Biotechnology), and then the mem-
T cells leads to  cell destruction and the development branes were stripped and reprobed with anti-GAPDH antibody
of type 1 diabetes. This process has been tied to both (Sigma) according to the manufacturer’s recommendations.
the CD1d locus and iNKT cells (Carnaud et al., 2001;
Shi et al., 2001; Wang et al., 2001). The deletion of the FACS Analysis
Cell staining was performed using -GalCer-loaded APC-labeledCD1 locus contributes to disease progression, and
CD1d-tetramer (kindly provided by A. Herbelin) and FITC-, Cyc- or-GalCer treatment results in amelioration of the disease
PE-conjugated mAbs. Labeled antibodies for flow cytometry in-(Sharif et al., 2001). Very recently it has been reported
cluded anti-CD161-Cyc, CD8-PE, CD25-PE, CD1a-PE, CD1d-PE,
that treatment of NOD mice with PPAR ligands sub- CD86-PE, CD83-PE, CD206-PE, CD3-FITC, CD36-FITC, CD80-FITC,
stantially reduced the development of type I diabetes CD209-FITC, HLA-DR-FITC, isotype-matched controls (BD Phar-
(Augstein et al., 2003). These findings are entirely consis- Mingen), anti-V11-PE, and anti-V24-FITC (Immunotech). The cells
were assessed for fluorescence intensity using EPICS Elite flowtent with the mechanism described here and warrant
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cytometer (Beckman Coulter) or with FACSCalibur cytometer (Beck- References
ton Dickinson). Data analysis was performed using WinMDI software
(Joseph Trotter, La Jolla, CA). Albert, M.L., Pearce, S.F., Francisco, L.M., Sauter, B., Roy, P., Sil-
verstein, R.L., and Bhardwaj, N. (1998). Immature dendritic cells
phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-Endocytosis
present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188,FITC-dextran (Sigma) was used to measure mannose receptor-
1359–1368.mediated endocytosis. Cells were incubated with 1 mg/ml FITC-
Augstein, P., Dunger, A., Heinke, P., Wachlin, G., Berg, S., Hehmke,dextran for 1 hr at 37
C (control at 0
C) and the uptake of
B., and Salzsieder, E. (2003). Prevention of autoimmune diabetes inFITC-dextran was determined by flow cytometry. Phagocytosis was
NOD mice by troglitazone is associated with modulation of ICAM-1measured by the cellular uptake of Latex beads (Sigma, carboxylate
expression on pancreatic islet cells and IFN-gamma expression inmodified, mean diameter 1 m): cells were incubated with latex
splenic T cells. Biochem. Biophys. Res. Commun. 304, 378–384.beads for 4 or 24 hr at 37
C (control at 0
C) and washed twice, and
the uptake was quantified by FACS. Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the
control of immunity. Nature 392, 245–252.
Mixed Leukocyte Reaction Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Della-
MDCs were collected, extensively washed, and used as stimulator bona, P., and Kronenberg, M. (1998). CD1d-mediated recognition
cells for allogeneic PBMC (2  105 cells/well). Stimulator cells were of an alpha-galactosylceramide by natural killer T cells is highly
added in graded doses to the T cells in 96-well flat-bottom tissue conserved through mammalian evolution. J. Exp. Med. 188, 1521–
culture plates. Cell proliferation was measured on day 5 by a 16 hr 1528.
pulse with [3H]thymidine (Amersham, 1 Ci/well). Calabi, F., Jarvis, J.M., Martin, L., and Milstein, C. (1989). Two
classes of CD1 genes. Eur. J. Immunol. 19, 285–292.
Expansion of iNKT Cells Carnaud, C., Gombert, J., Donnars, O., Garchon, H., and Herbelin,
IDCs were treated with or without the inflammatory mixture as de- A. (2001). Protection against diabetes and improved NK/NKT cell
scribed previously and with 100 ng/ml -GalCer for 24 hr to obtain performance in NOD.NK1.1 mice congenic at the NK complex. J.
-GalCer-loaded MDC or IDC, respectively. -GalCer pulsed IDCs Immunol. 166, 2404–2411.
or MDCs (1  105 cells) were cocultured with 1  106 monocyte
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans,depleted autologous PBMC for 5 days in 24-well plates. The expan-
R.M. (2001a). PPAR-gamma dependent and independent effects onsion of iNKT cells was monitored by quantifying V24 V11 and
macrophage-gene expression in lipid metabolism and inflammation.V24 CD161 cells by FACS analysis. The specificity of CD1d-
Nat. Med. 7, 48–52.restricted NKT cells was also verified by -GalCer-loaded APC-
Chawla, A., Boisvert, W.A., Lee, C.H., Laffitte, B.A., Barak, Y., Jo-labeled CD1d tetramer staining.
seph, S.B., Liao, D., Nagy, L., Edwards, P.A., Curtiss, L.K., et al.
(2001b). A PPAR gamma-LXR-ABCA1 pathway in macrophages isMicroarray Experiment
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of this receptor by IL-13. Immunity 19, 329–339.normalized by comparing to the median signal (arbitrary value of 1.0).
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